Tumor Biology

, Volume 37, Issue 5, pp 6255–6260 | Cite as

MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma

  • Wei Ding
  • Hongbo Tan
  • Chen Zhao
  • Xuemei Li
  • Zhiqiang Li
  • Changli Jiang
  • Yue Zhang
  • Lan Wang
Original Article


MicroRNAs (miRNAs) play key roles in cancer development and progression. In the present study, we investigated the role of miR-145 in the progression of hepatocellular carcinoma (HCC). Ten HCC cell lines and samples from 96 patients with HCC were analyzed for the expression of miR-145 by quantitative real-time polymerase chain reaction (qRT-PCR). Overexpression of miR-145 was established by transfecting mimics into HepG2 and QGY-7703 cells. Cell proliferation and cell migration were assessed by cell viability assay and transwell assay. Western blot was to verify ROCK1 as a novel target gene of miR-145. Our results showed that miR-145 was frequently downregulated in HCC tumors and cell lines. Overexpression of miR-145 in HCC cell lines significantly inhibited cell proliferation, migration, and invasion in vitro. ROCK1 was identified as a target of miR-145, and ectopic expression of miR-145 downregulated ROCK1. Together, these findings indicate that miR-145 acts as a tumor suppressor and its downregulation in tumor tissues may contribute to the progression and metastasis of HCC through a mechanism involving ROCK1, suggesting miR-145 as a potential new diagnostic and therapeutic target for the treatment of HCC.


MiR-145 Hepatocellular carcinoma ROCK1 Proliferation Migration 



This study was supported by National Natural Science Foundation of China grant (No. 81360274 and No. 31200657).

Compliance with ethical standards

Conflicts of interest


Informed consents

All specimens were collected in accordance with informed consents of patients, and all procedures complied with the protocol approved by the Ethical Committee of Kunming General Hospital.


  1. 1.
    Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis. 2001;19:263–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Kloosterman W, Plasterk R. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.CrossRefPubMedGoogle Scholar
  8. 8.
    Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Lakshmipathy U, Love B, Adams C, Thyagarajan B, Chesnut JD. Micro RNA profiling: an easy and rapid method to screen and characterize stem cell populations. Methods Mol Biol. 2007;407:97–114.CrossRefPubMedGoogle Scholar
  11. 11.
    Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1:882–91.PubMedGoogle Scholar
  12. 12.
    Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, et al. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia. 2013;15:218–30.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMedGoogle Scholar
  14. 14.
    Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102:883–91.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem. 2013;61:185–98.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ma W, Wong CC, Tung EK, Wong CM, Ng IO. RhoE is frequently downregulated in HCC and suppresses HCC invasion through antagonizing the Rho/ROCK/MYPT pathway. Hepatology. 2012;57:152–61.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Wei Ding
    • 1
  • Hongbo Tan
    • 2
  • Chen Zhao
    • 3
  • Xuemei Li
    • 1
  • Zhiqiang Li
    • 4
  • Changli Jiang
    • 1
  • Yue Zhang
    • 1
  • Lan Wang
    • 1
  1. 1.Department of Clinical LaboratoryKunming General Hospital, Chinese People’s Liberation ArmyKunmingChina
  2. 2.Department of OrthopedicsKunming General Hospital of Chinese People’s Liberation ArmyKunmingChina
  3. 3.Department of Clinical HematologyThird Military Medical UniversityChongqingChina
  4. 4.Division of Cellular and Molecular Diagnostics, Center of Laboratory MedicineChengdu Military General HospitalChengduChina

Personalised recommendations